Genmab

	13/10 13:48 af Plimsoller	Indeed, but other countries also came into a hold the first time around, and the saIe is still on track. I must admit that I don't see the big difference compared to Q1/Q2, other than everyone being better prepared. I hope that I am right and you are wrong - primarily for the patients` sake!
	13/10 13:47 af E L	Denmark seems to be doing really wel atm compared with others, NL actually rather bad; situation worsened super fast over the past few weeks. as in other countries
	13/10 13:45 af Plimsoller	Ok. You may be right. In Denmark we see an increase in numbers (infected, which is also due to the extensive testing, and hospitalised people, both which seem to be moving in the right direction at the moment. In addition people spend less time in the hospitals with the disease than they did at the earlier stages. This due to better treatment, but it also seems like the segment of people in the hospitals is different this time around (that can of course change).
	13/10 13:43 af Bulder	STOCKHOLM (Nyhetsbyrån Direkt) Johnson & Johnson, en amerikansk tillverkare av hälso- och sjukvårdsprodukter, spår en försäljning för helåret 2020 om 82,0-82,8 miljarder dollar. Det framgår av delårsrapporten. Bolaget förväntade sig tidigare en försäljning mellan 81,0 och 82,5 miljarder dollar.
	13/10 13:42 af Bulder	JnJ has already revised it's sales for 2020 upwards
	13/10 13:39 af E L	SC is already helping in care, but not enough yet i think, i doubt we are seeing home administration yet on a large scale
	13/10 13:38 af E L	I think if we make $4bn in Dara sales this year, that is an amazing accomplishment given current situation
	13/10 13:37 af E L	did I?
	13/10 13:37 af E L	and already the level of care never recovered over the summer to the level before covid
	13/10 13:37 af peter12	EL why did you sell your GMAB ? ;-)
	13/10 13:35 af E L	Because we see so many patients going into hospitals again with Covid, like Q1, Q2. Many countries are locking down partially again ,in NL hospitals are already scaling down regular care and are already canceling some standard procedures/surgical as hospital/ staf capacity is needed for Covid :(
	13/10 13:29 af Plimsoller	Why do you think that the situation in Q4 will be more difficult than the situation was in Q1/Q2 E L?
	13/10 13:25 af E L	i think we could see a very difficult situation in Q4 in hospitals and cancer care unfortunately
	13/10 13:25 af Bulder	If US repeats +19% in Q4, they will end in the very top of the interval.
	13/10 13:23 af E L	yes. i would not expect an upgrade in these uncertain times.
	13/10 13:23 af Bulder	Hvad var Genmabs årsguidning? Var det ikke 3,9-4,2?
	13/10 13:21 af Helge Larsen/PI-redaktør	J&J leverer bedre end ventet salg drevet af Darzalex(link)
	13/10 13:17 af peter12	Det svarer til et recepttal for september på 247M ? Mon ikke det lugter af opjustering senere ?
	13/10 13:13 af svak	7,2 % bedre end concensus er da vær at tage med :)
	13/10 13:10 af Bulder	Det tager måske lidt længere tid for sc at slå igennem i row?
	13/10 12:59 af AaBforever	Så er jeg mere rolig..:-D
	13/10 12:54 af AaBforever	DK -0,04%
	13/10 12:53 af kkjoel	sc kan vise sig at være en langt vigtigere konkurranceparameter end nogen havde turdet forestille sig! (undtagen JvW og McJean, naturligvis :-)
	13/10 12:52 af Bulder	Us up 19%!

	13/10 12:51 af kkjoel	sc is really making an impact, huh?!
	13/10 12:49 af Bulder	No problem reaching +4bn
	13/10 12:48 af Bulder	also better than mine ;-)
	13/10 12:46 af BioShare	USD 1,099 million in the third quarter of 2020. Net trade sales were USD 585 million in the U.S. and USD 514 million in the rest of the world.
	13/10 12:46 af E L	big landmark > 1bn $ quarter
	13/10 12:45 af E L	better as my forecast ;-)
	13/10 12:45 af E L	excellent
	13/10 12:45 af GeorgeBest	Bedre end consensus
	13/10 12:45 af GeorgeBest	1099M USD
	13/10 12:27 af Helge Larsen/PI-redaktør	-88% er vel ikke at "blive handlet ned"?
	13/10 12:14 af nohope	Der er altid nogen, der ved noget på forhånd - og de er igang med at handle aktien ned...
	13/10 11:48 af iboge	Ok, tak.
	13/10 11:46 af iboge	Hvilket tidspunkt kommer de med Q3 ?
	13/10 09:54 af Helge Larsen/PI-redaktør	COMy 2020 \| The benefits of bispecific antibodies for treating multiple myeloma(link)
	13/10 09:51 af E L	CD37：/ Genmab for the chinese speakers (link) ;-)
	13/10 09:50 af E L	FDA also gave orphan designation to Dara SC for amyloidosis the other day, not sure if that was mentioned
	13/10 08:51 af Helge Larsen/PI-redaktør	FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma: (link)
	13/10 08:02 af Helge Larsen/PI-redaktør	:-)
	13/10 07:41 af bibob	Scottish medicines consortium accept Dara sc. (link)
	13/10 07:40 af bibob	God morgen. :-).
	13/10 07:18 af Helge Larsen/PI-redaktør	uciano J Costa @End_myeloma · 8 t Accrual completed for 123 patients on MASTER study with enrichment for high risk #mmsm!! I am most proud of the collaboration fostered in the COMMIT consortium. 20% patients 70 or older, 24% minorities. We "COMMIT" to 25%+ minorities in future trials.(link)
	13/10 07:01 af Helge Larsen/PI-redaktør	God morgen. :-)
	12/10 23:50 af transalp	:)
	12/10 22:50 af Legolas23	Prop på, pensionist. Nu! :-)
	12/10 21:28 af Sukkeralf	(link)
	12/10 21:15 af Solsen	Omkring 22 kr. Jeg vil gerne tro dig Mcjean. Men jeg opfatter det mere som et håb.